194 related articles for article (PubMed ID: 9751338)
1. Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy.
Jahnson S; Karlsson MG
J Urol; 1998 Oct; 160(4):1291-6. PubMed ID: 9751338
[TBL] [Abstract][Full Text] [Related]
2. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
[TBL] [Abstract][Full Text] [Related]
3. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer.
Pollack A; Wu CS; Czerniak B; Zagars GK; Benedict WF; McDonnell TJ
Clin Cancer Res; 1997 Oct; 3(10):1823-9. PubMed ID: 9815569
[TBL] [Abstract][Full Text] [Related]
4. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
5. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
[TBL] [Abstract][Full Text] [Related]
6. Expression of bcl-2 and bcl-X in bladder cancer.
Kirsh EJ; Baunoch DA; Stadler WM
J Urol; 1998 Apr; 159(4):1348-53. PubMed ID: 9507882
[TBL] [Abstract][Full Text] [Related]
7. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha.
Esuvaranathan K; Chiong E; Thamboo TP; Chan YH; Kamaraj R; Mahendran R; Teh M
Cancer; 2007 Mar; 109(6):1097-105. PubMed ID: 17311305
[TBL] [Abstract][Full Text] [Related]
10. p53 predictive value for pT1-2 N0 disease at radical cystectomy.
Shariat SF; Lotan Y; Karakiewicz PI; Ashfaq R; Isbarn H; Fradet Y; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Montorsi F; Müller SC; Karam JA; Heukamp LC; Netto G; Lerner SP; Sagalowsky AI; Cote RJ
J Urol; 2009 Sep; 182(3):907-13. PubMed ID: 19616250
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of nuclear p53 and tumor progression in bladder cancer.
Esrig D; Elmajian D; Groshen S; Freeman JA; Stein JP; Chen SC; Nichols PW; Skinner DG; Jones PA; Cote RJ
N Engl J Med; 1994 Nov; 331(19):1259-64. PubMed ID: 7935683
[TBL] [Abstract][Full Text] [Related]
13. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.
Chatterjee SJ; Datar R; Youssefzadeh D; George B; Goebell PJ; Stein JP; Young L; Shi SR; Gee C; Groshen S; Skinner DG; Cote RJ
J Clin Oncol; 2004 Mar; 22(6):1007-13. PubMed ID: 14981105
[TBL] [Abstract][Full Text] [Related]
14. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
Hum Pathol; 2006 Dec; 37(12):1568-76. PubMed ID: 16949911
[TBL] [Abstract][Full Text] [Related]
15. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53.
Cote RJ; Dunn MD; Chatterjee SJ; Stein JP; Shi SR; Tran QC; Hu SX; Xu HJ; Groshen S; Taylor CR; Skinner DG; Benedict WF
Cancer Res; 1998 Mar; 58(6):1090-4. PubMed ID: 9515785
[TBL] [Abstract][Full Text] [Related]
16. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy.
Shariat SF; Karakiewicz PI; Ashfaq R; Lerner SP; Palapattu GS; Cote RJ; Sagalowsky AI; Lotan Y
Cancer; 2008 Jan; 112(2):315-25. PubMed ID: 18008359
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of p53 and proliferating cell nuclear antigen (PCNA) in bladder cancer: positive immunostaining and radiosensitivity.
Ogura K; Habuchi T; Yamada H; Ogawa O; Yoshida O
Int J Urol; 1995 Nov; 2(5):302-8. PubMed ID: 8749948
[TBL] [Abstract][Full Text] [Related]
18. Clonal analysis of human recurrent superficial bladder cancer by immunohistochemistry of P53 and retinoblastoma proteins.
Chern HD; Becich MJ; Persad RA; Romkes M; Smith P; Collins C; Li YH; Branch RA
J Urol; 1996 Nov; 156(5):1846-9. PubMed ID: 8863629
[TBL] [Abstract][Full Text] [Related]
19. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors.
Cordon-Cardo C; Zhang ZF; Dalbagni G; Drobnjak M; Charytonowicz E; Hu SX; Xu HJ; Reuter VE; Benedict WF
Cancer Res; 1997 Apr; 57(7):1217-21. PubMed ID: 9102201
[TBL] [Abstract][Full Text] [Related]
20. The relation between p53 overexpression and lymph node metastases in clinical stage t2 and t3a transitional cell bladder carcinoma.
Uygur MC; Yaman I; Kutluay L; Altuğ U; Erol D
J Exp Clin Cancer Res; 1999 Sep; 18(3):391-5. PubMed ID: 10606186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
